1. Opening Hook
Jagsonpal just reminded the market that “flattish” is not a typo—it’s a lifestyle choice for Q3.
While pharma peers were busy riding price hikes, Jagsonpal chose introspection, SKU pruning, and some spiritual cleansing of its sales force. Growth paused, patience tested, and management optimism was served extra hot.
The quarter didn’t collapse, didn’t excite, and didn’t lie. It simply waited.
Between GST aftershocks, labour code déjà vu, and a leadership reshuffle, this was less a performance quarter and more a therapy session.
But here’s the twist: cash kept piling up, margins behaved, and management is suddenly very confident about Q4.
Suspiciously confident.
Read on—because the real story is hiding behind phrases like “resource reallocation” and “betting on winning horses.” 😏
2. At a Glance
- Revenue ₹73 cr (Flat YoY) – Growth went on a coffee break, forgot to return.
- 9M Revenue +6% YoY – Slow, but still breathing.
- EBITDA ₹16.7 cr – Margins stayed loyal when sales didn’t.
- EBITDA Margin 22.7% – Pharma math still works.
- PAT ₹12.5 cr (+10% YoY) – Profits quietly doing their job.
- Cash ₹176 cr – Balance sheet flexing harder than operations.
- Stock cash inflow ₹15 cr in Q3 – Cash doesn’t care about growth narratives.
3. Management’s Key Commentary (Decoded)
“The quarter was at best flattish.”
(Translation: Don’t ask us to sugarcoat it—we tried.) 😐
“We refreshed strategies under new leadership.”
(Translation: We broke a few things to fix bigger ones.)
“Growth will accelerate to double digits from Q4.”
(Translation: Please judge us after March, not December.) 😏
“RPM grew
